SynthesisNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
Heterogeneous brain alterations in treatment-resistant depression converge on common control networks.
Synthesis in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Converging on control: Rethinking treatment-resistant depression through network neuroscience.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Treatment-resistant depression (TRD) imposes a substantial clinical and societal burden. However, it remains unclear whether neuroimaging abnormalities associated with TRD converge onto specific large-scale brain networks. We systematically reviewed neuroimaging articles comparing patients with TRD to both healthy controls (HCs) and patients with non-treatment-resistant depression (non-TRD), encompassing functional and structural imaging modalities. Using a validated coordinate network mapping (CNM) approach and a normative human brain connectome, we derived TRD-associated networks. Overlap analyses with canonical large-scale networks were performed to delineate the functional architecture of these networks. In addition, spatial correlations between TRD-associated probability maps and whole-brain neurotransmitters density maps to explore potential neurochemical substrates. In the TRD-HC contrast, TRD-associated functional and structural networks were distributed across frontal, cingulate, insular, striatal, and thalamic regions, showing their greatest overlap with the frontoparietal (FPN) and cingulo-opercular network (CON). In the TRD-non-TRD contrast, TRD-associated functional and structural networks were more selectively localized, with predominant overlap confined to the CON. Spatial correlation analyses further anchored these network-level abnormalities to glutamatergic, dopaminergic, and monoaminergic neurotransmitter systems. These findings indicate that the general neurobiological burden of TRD is anchored within large-scale control networks involving the FPN and CON, whereas treatment resistance is characterized by more focal alterations within the CON. This network-based dissociation provides insight into the neural organization of TRD and highlights potential circuit-level targets for therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.